aTyr Pharma

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Protein biosynthesis, Biology, aTyr Pharma, Aminoacyl tRNA synthetase, Transfer RNA, Signal transduction

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Key Points: 
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President

Retrieved on: 
Monday, August 2, 2021
aTyr Pharma, Lumos, Pharma

I am excited to announce the promotion of John to President as part of the Lumos Pharma succession planning undergone by the Company and our Board of Directors, commented Rick Hawkins, Chairman and CEO of Lumos Pharma.

Key Points: 
  • I am excited to announce the promotion of John to President as part of the Lumos Pharma succession planning undergone by the Company and our Board of Directors, commented Rick Hawkins, Chairman and CEO of Lumos Pharma.
  • Our interactions over this period and Johns contributions as COO and Chief Scientific Officer at Lumos Pharma support our decision to turn over more responsibility to him.
  • At Lumos Pharma, Dr. McKew has served as Chief Operating Officer since April 2020 and as Chief Scientific Officer since he joined the company in 2016.
  • Prior to Lumos Pharma, Dr. McKew served as Vice President of Research at aTyr Pharma where he led a research team discovering and advancing protein-based therapeutics for rare diseases.

aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung

Retrieved on: 
Thursday, July 29, 2021
Protein biosynthesis, Autoimmune diseases, Lung disorders, Branches of biology, Histidine—tRNA ligase, Transfer RNA, Biology, Aminoacyl tRNA synthetase, Sarcoidosis, Chemistry, aTyr Pharma, Xiang-Lei Yang

11,072,787 entitled, Histidyl-tRNA synthetase-FC conjugates, covers the use of the companys lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung.

Key Points: 
  • 11,072,787 entitled, Histidyl-tRNA synthetase-FC conjugates, covers the use of the companys lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung.
  • ATYR1923 is a Fc fusion protein based on the N terminal fragment of histidyl-tRNA synthetase that is currently in clinical development for the treatment of pulmonary sarcoidosis and is being evaluated in other inflammatory lung diseases.
  • These patents encompassed important new therapeutic modalities which underpin the broad pipeline of novel therapeutics in active development at the company.
  • aTyr is developing ATYR1923 as a potential therapeutic for patients with inflammatory lung diseases.

aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

Retrieved on: 
Thursday, July 8, 2021
Autoimmune diseases, Abdominal pain, Sarcoidosis, aTyr Pharma

We are pleased to complete the last patient visit in this important study, which represents a significant milestone for aTyr, our ATYR1923 clinical program and the sarcoidosis community, said Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.

Key Points: 
  • We are pleased to complete the last patient visit in this important study, which represents a significant milestone for aTyr, our ATYR1923 clinical program and the sarcoidosis community, said Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.
  • We would like to thank all of the patients, investigators and the Foundation for Sarcoidosis Research for their support and efforts that helped make this possible.
  • aTyr is developing ATYR1923 as a potential therapeutic for patients with severe inflammatory lung diseases.
  • aTyr has completed enrollment in a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis.

aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis

Retrieved on: 
Wednesday, June 23, 2021
aTyr Pharma, Autoimmune diseases, Sarcoidosis, Medicine, Medical specialties, Clinical medicine

SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will host a virtual Key Opinion Leader (KOL) event on the current treatment options for pulmonary sarcoidosis on Tuesday, June 29th at 5:00pm ET/2:00pm PT.

Key Points: 
  • SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will host a virtual Key Opinion Leader (KOL) event on the current treatment options for pulmonary sarcoidosis on Tuesday, June 29th at 5:00pm ET/2:00pm PT.
  • Dr. Culver will discuss the current standard of care and unmet medical need for patients with pulmonary sarcoidosis, including the side effects associated with long-term steroid use and need for steroid sparing agents.
  • Dr. Culver and Dr. Shukla will be available for a live Q&A session as part of the event.
  • aTyr has completed enrollment in a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis.

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

Retrieved on: 
Thursday, June 10, 2021
Integral membrane proteins, Membrane proteins, Transmembrane proteins, Single-pass transmembrane proteins, Transmembrane receptors, Neuropilin 2, Neuropilin, Semaphorin, E-selectin, aTyr Pharma

The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.

Key Points: 
  • The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.
  • Class 3 Semaphorins are an important set of NRP2 ligands, with recent data implicating their role in sustaining chronic inflammation.
  • Details of the abstract and poster presentation are as follows:
    The poster is also available on the aTyr website.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen

Retrieved on: 
Tuesday, May 25, 2021
aTyr Pharma, John Mendlein, Health care, Economy of the United States

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Sara Zaknoen, M.D., to the companys Board of Directors.

Key Points: 
  • SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Sara Zaknoen, M.D., to the companys Board of Directors.
  • We are very pleased to welcome Sara, a highly accomplished executive with experience in drug development, to our Board of Directors, said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.
  • Through her company, Zed Strategic Consulting, Dr. Zaknoen has worked as a clinical drug development consultant with large pharma and biotech companies across multiple disease indications since 2014.
  • Previously, Dr. Zaknoen held Chief Medical Officer positions at several biotechnology companies, including Ignyta, Inc., Polynoma LLC, Tragara Pharmaceuticals, Inc. and Cabrellis Pharmaceuticals Corporation.

aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810

Retrieved on: 
Wednesday, May 19, 2021
Branches of biology, Medical specialties, Medicine, Neuropilin 2, Immunology, Vascular endothelial growth factor, Monoclonal antibody, aTyr Pharma

ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF.

Key Points: 
  • ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF.
  • ATYR2810 is the first Investigational New Drug (IND) candidate to arise from aTyr\xe2\x80\x99s in-house research program designing monoclonal antibodies to selectively target the NRP2 receptor and its associated signaling pathways.
  • Preclinical data suggest that ATYR2810 could be effective against certain types of solid tumors.
  • aTyr\xe2\x80\x99s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.

aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update

Retrieved on: 
Thursday, May 13, 2021
Medical specialties, Health, COVID-19, Occupational safety and health, Public health, Zoonoses, Antibody, aTyr Pharma

Our manufacturing agreement with Lonza for the production of this antibody reflects our commitment to this program.

Key Points: 
  • Our manufacturing agreement with Lonza for the production of this antibody reflects our commitment to this program.
  • Data is expected in the third quarter of this year.\nReported positive results from its Phase 2 study of ATYR1923 in COVID-19 patients with severe respiratory complications, which provided proof-of-mechanism for ATYR1923.
  • Research and development expenses were $4.5 million and $3.6 million for the three months ended March 31, 2021 and 2020, respectively.
  • Links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts.

aTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research

Retrieved on: 
Tuesday, May 11, 2021
aTyr Pharma, Nangle

b'SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the promotion of Leslie Nangle, Ph.D., to Vice President, Research.

Key Points: 
  • b'SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the promotion of Leslie Nangle, Ph.D., to Vice President, Research.
  • Dr. Nangle will serve as a member of the company\xe2\x80\x99s executive leadership team, managing research and scientific operations.
  • Dr. Nangle has served in scientific research roles at aTyr since joining the company in 2007, including most recently as Senior Director and Head of Research.\n\xe2\x80\x9cDr.
  • Nangle has been an integral part of our team and we are delighted to have her lead aTyr\xe2\x80\x99s research efforts,\xe2\x80\x9d said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.